According to a study involving scientists from the University of North Carolina at Chapel Hill, persistent infection with human papillomavirus (HPV) could be a useful clinical marker for increased risk of cervical cancer, the second most common cancer in women worldwide.

HPV is a sexually transmitted virus that can cause high-grade cervical lesions, increasing a woman's risk of developing invasive cervical cancer.

Currently, Pap smear tests are widely used in screening programs aimed at detecting changes in the cervix before a cancer develops. However, testing for HPV infections has the potential to be more sensitive for future cervical cancer screening programs.

In the study -- thought to be the first of its kind -- scientists reviewed 41 existing studies including over 22,500 women to systemically evaluate the association between HPV persistence and high-grade lesions or cervical cancer.

Jennifer Smith, Ph.D., research assistant professor of epidemiology in the UNC School of Public Health and senior author of the paper, said: "We found that a persistent HPV infection of six months to one year was consistently associated with a woman's increased risk of high-grade cervical lesions or cervical cancer."

Smith is also a member of the UNC Lineberger Comprehensive Cancer Center.

There are approximately 14 high-risk types of HPV that cause invasive cervical cancer. The two most common types are 16 and 18, which have different viral genetic patterns. These virus types are responsible for about 70 percent of invasive cervical cancer and 50 percent of high-grade lesions worldwide.

"The next step will be to develop a consensus definition of HPV 'persistence' that can then usefully inform clinical practice for future cervical cancer screening programs," Smith said. "Additionally, we need more information on whether the persistence of specific HPV types -- such as 16 or 18 -- is associated with relative differences in increased risk."

"In the future, measuring persistence of HPV infection may optimize screening for cervical cancer by increasing sensitivity while maintaining comparable specificity to Pap smear testing," Smith said. "What that means, essentially, is that we might be better able to identify potential cervical cancer cases that could otherwise go undetected."

Other study authors include Jill Koshiol, Ph.D., a former doctoral student at the School of Public Health and now a cancer prevention fellow at the National Cancer Institute; Charles Poole, Sc.D., an associate professor of epidemiology in the School of Public Health; and several investigators from GlaxoSmithKline.

Note: If no author is given, the source is cited instead.

• Cervical Cancer
• Cancer
• Breast Cancer
• Men's Health
• Prostate Cancer
• Colon Cancer

• Pap smear
• HPV vaccine
• Cervical cancer
• HPV
• Vulvovaginal health
• Trichomoniasis